Anti-αvβ3 humanized monoclonal antibodies
US7504102B2 · kind B2 · utility
0Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2006 |
| Grant date | Mar 17, 2009 |
| Priority date | — |
| Expiry date | Nov 9, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin αvβ3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of αvβ3-mediated disorders, such as restenosis, in human patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.